Elequin Capital’s Labcorp LH Stock Holding History

Elequin Capital’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43	Closed	-$9.86K	–	496
2024 Q4	$9.86K	Buy	+43	New	+$9.86K	﹤0.01%	341

Other funds holding LH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Diamond Hill Capital Management Columbus, Ohio $16B AUM 4.15% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Elequin Capital's LH Position: Q1 2025 in Review

Elequin Capital sold out of Labcorp (LH) in Q1 2025, closing a stake of 43 shares — an estimated $9.86K sold.

Elequin Capital first reported a position in LH in Q4 2024 and held it in 1 quarter. The position peaked at $9.86K in Q4 2024. 972 funds tracked by Wall St. Rank hold LH as of Q1 2025.

Elequin Capital reported no remaining Labcorp position as of Q1 2025 after selling out during the quarter.
Elequin Capital sold 43 Labcorp shares in Q1 2025, an estimated $9.86K.
Elequin Capital first reported a position in Labcorp in Q4 2024 and held it in 1 quarter.
Elequin Capital's Labcorp position peaked at $9.86K in Q4 2024.
972 funds tracked by Wall St. Rank held Labcorp as of Q1 2025.

Based on Elequin Capital's 13F filing for Q1 2025, filed 13 May 2025.